AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...

AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...

AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the ...

AbbVie (NYSE:ABBV) said it has received FDA approval for its intravenous antibiotic treatment Emblaveo. The FDA approved Emblaveo, a combination of aztreonam and avibactam, for use in combination with ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

Although a waiver was placed on HIV/AIDS programmes in last month's U.S. foreign aid funding freeze, many concerns remained about the future of treatment programmes, the deputy executive director of ...

Pfizer’s Emblaveo has been approved in the EU with ... including the US and Canada, where AbbVie holds rights. Use of the drug will likely be reserved for patients who have exhausted other ...

(Avibactam sodium + aztreonam) is under clinical development by AbbVie and currently in Pre-Registration for ... Avibactam sodium and Aztreonam (Emblaveo) is a fixed dose combination acts as ...